Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Participants
942
clinicaltrials.gov
Lead sponsor
Sanofi
clinicaltrials.gov
Start date
2025-09-16
clinicaltrials.gov
Number of sites
314
clinicaltrials.gov

Summary
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
clinicaltrials.gov
Acronym
PERSEPHONE
clinicaltrials.gov
Short title
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
clinicaltrials.gov
Official title
A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
clinicaltrials.gov

Control arm
Placebo
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2030-01-22
clinicaltrials.gov
First posted
2025-09-24
clinicaltrials.gov
Registry last updated
2026-10-19
clinicaltrials.gov
Primary completion date
2029-11-27
clinicaltrials.gov
Start date
2025-09-16
clinicaltrials.gov

Participants
942
clinicaltrials.gov
Participant count basis
Estimated
clinicaltrials.gov
Planned participants
942
clinicaltrials.gov
Protocol amendments
2
clinicaltrials.gov
Number of sites
314
clinicaltrials.gov

Data monitoring committee
Yes
clinicaltrials.gov
Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Sanofi
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT07190209
clinicaltrials.gov
ClinicalTrials.gov ID
NCT07190209
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Parallel groups
Purpose
Treatment
Masking
Quadruple masking
Masked roles
Participants, Care providers, Investigators, Outcome assessors
Sources for study design
clinicaltrials.gov

  1. Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations

    Timeframe: From Baseline up to 48 weeks

    The annualized moderate or severe COPD exacerbation rate up to 48 weeks treatment period compared to placebo

  1. Change from baseline in post-Bronchodilator Forced Expiratory Volume in 1 second (post-BD FEV1)

    Timeframe: From Baseline up to 48 weeks

    The post-Bronchodilator Forced Expiratory Volume in 1 second is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

  2. Change from baseline in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1)

    Timeframe: From Baseline up to 48 weeks

    The pre-Bronchodilator Forced Expiratory Volume in 1 second is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

  3. Change from baseline in the SGRQ-C total score

    Timeframe: From Baseline up to 48 weeks

    The St. George's Respiratory Questionnaire for patients with chronic obstructive pulmonary disease is derived from the St. George's Respiratory Questionnaire (SGRQ) and is designed to measure and quantify health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100 with lower scores indicating better quality-of-life.

  4. SGRQ responder defined as an improvement of ≥4 points in the SGRQ-C total score

    Timeframe: From Baseline up to 48 weeks

  5. Change from baseline in the Chronic airways assessment Test (CAAT) score

    Timeframe: From Baseline up to 48 weeks

    The CAAT is an 8-item patient-reported outcome (PRO) measure designed to assess the impact of chronic airways diseases, including COPD, on patients' health status. The CAAT has a scoring range of 0-40, with higher scores indicating a greater impact of the disease on health status.

  6. CAAT responder defined as an improvement of ≥2 points in the CAAT total score

    Timeframe: From Baseline up to 48 weeks

  7. Change from baseline in the E-RS:COPD total score

    Timeframe: From Baseline up to 48 weeks

    The Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) is an 11-item patient-reported outcome (PRO) measure that evaluates the severity of respiratory symptoms in patients with stable COPD. The total score ranges from 0 to 40, with higher scores indicating more severe respiratory symptoms.

  8. E-RS:COPD responder defined as an improvement of ≥2 points in the E-RS:COPD total score

    Timeframe: From Baseline up to 48 weeks

  9. Annualized rate of severe COPD exacerbations

    Timeframe: From Baseline up to 48 weeks

  10. Time to first moderate or severe COPD exacerbation

    Timeframe: From Baseline up to 48 weeks

    Time to first occurrence of moderate to severe COPD exacerbation up to 48 weeks

  11. Time to first severe COPD exacerbation

    Timeframe: From Baseline up to 48 weeks

    Time to first occurrence of severe COPD exacerbation up to 48 weeks

  12. Incidence of participants with TEAEs, including AESIs, and SAEs

    Timeframe: From Baseline up to 56 weeks

    Treatment-Emergent Adverse Events (TEAEs), Adverse events of Special Interest (AESIs), Serious Adverse Events (SAEs)

  13. Incidence of potentially clinically significant laboratory abnormalities

    Timeframe: From Baseline up to 56 weeks

  14. Serum concentration of lunsekimig

    Timeframe: From Baseline up to 48 weeks

  15. Incidence and titer of antidrug antibodies (ADAs)

    Timeframe: From Baseline up to 48 weeks

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
40 Years
Maximum age
80 Years
Healthy volunteers
No

  • Between 40 to 80 years of age
  • Physician diagnosed chronic obstructive pulmonary disease (COPD) ≥1 year
  • Post-bronchodilator forced expiratory volume in 1 second (post-BD FEV1) ≥ 20% and ≤ 70% of predicted value and FEV1/FVC (forced expiratory volume in 1 second /forced vital capacity) <0.70
  • Former or current smokers ≥10 pack-years
  • Chronic Airways Assessment Test (CAAT) ≥10
  • ≥2 moderate or ≥1 severe COPD exacerbations in the prior year
  • Triple (ICS+LABA+LAMA) COPD therapy ≥12 consecutive weeks
  • EOS (blood eosinophil count) ≥ 150 cells/μL
  • 18.0 ≤ Body Mass Index ≤ 40.0 kg/m2

Participants are excluded from the study if any of the following criteria apply:

  • Asthma, including pediatric asthma, or asthma-COPD overlap syndrome (ACOS)

  • Significant pulmonary disease other than COPD

  • Long-term oxygen therapy >4.0 L/min or requirement of >2.0 L/min to maintain oxygen saturation >88% at rest

  • Unstable disorder that can impact participants safety or study outcomes

  • Active or incompletely treated tuberculosis

  • Current or past malignancies

  • Concomitant therapies:

    • long-term macrolides or phosphodiesterase Type 3 (PDE-3) or PDE-4 inhibitors unless on stable therapy for >6 months
    • any biologic therapy or systemic immunosuppressant within 4 months or 5 half-lives prior to Screening

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Sources for eligibility
clinicaltrials.gov

  • Chandler Clinical Research Trials- Site Number : 8400025Chandler, United StatesRecruiting
  • Pulmonary Associates - Phoenix - East Bell Road- Site Number : 8400114Phoenix, United StatesRecruiting
  • Epic Medical Research - Surprise- Site Number : 8400096Surprise, United StatesRecruiting
  • IMAX Clinical Trials- Site Number : 8400109La Palma, United StatesRecruiting
  • Long Beach Research Institute- Site Number : 8400027Long Beach, United StatesRecruiting
  • Downtown L.A. Research Center- Site Number : 8400009Los Angeles, United StatesRecruiting
  • Newport Native MD- Site Number : 8400003Newport Beach, United StatesRecruiting
  • Paradigm Research - Redding- Site Number : 8400108Redding, United StatesRecruiting
  • Amicis Research Center - Valencia- Site Number : 8400119Valencia, United StatesRecruiting
  • Helix Biomedics- Site Number : 8400065Boynton Beach, United StatesRecruiting
  • Beautiful Minds Clinical Research Center- Site Number : 8400017Cutler Bay, United StatesRecruiting
  • Solution Clinical Research- Site Number : 8400039Doral, United StatesCompleted
  • Eastern Medical Group Research- Site Number : 8400020Fort Myers, United StatesRecruiting
  • Premier Medical Associates- Site Number : 8400012Lady Lake, United StatesCompleted
  • University of Miami Dermatology Clinical Trials Unit- Site Number : 8400078Miami, United StatesRecruiting
  • MCR Research- Site Number : 8400004Miami, United StatesRecruiting
  • Nuren Medical & Research Center- Site Number : 8400030Miami, United StatesRecruiting
  • My Community Research Center- Site Number : 8400164Miami, United StatesRecruiting
  • Reed Medical Research Corp- Site Number : 8400167Miami, United StatesRecruiting
  • Deluxe Health Center- Site Number : 8400010Miami Lakes, United StatesRecruiting
  • Omega Research Consultants - Orlando - Forest City- Site Number : 8400015Orlando, United StatesRecruiting
  • Pharmakon Medical Research- Site Number : 8400156Palm Beach Gardens, United StatesRecruiting
  • Broward Research Center - Pembroke Pines- Site Number : 8400053Pembroke Pines, United StatesRecruiting
  • Clinical Research Trials of Florida- Site Number : 8400011Tampa, United StatesRecruiting
  • Deluxe Health Center-Tampa- Site Number : 8400056Tampa, United StatesRecruiting

And 289 more, listed on the interactive page.

Sources for sites
clinicaltrials.gov

  • 2024-518016-39-00
  • U1111-1308-9892
Sources for references
clinicaltrials.gov

Related records

Drugs (1)

Lead sponsors (1)

Conditions (1)